-
20Dec, 2023
Inter Partes Review (IPR) challenges On 16 March 2023, Mylan Pharmaceuticals Inc. (Mylan) filed petitions for Inter Partes Review (IPR) against Novo Nordisk's semaglutide compound patents (US Paten...
-
20Dec, 2023
Update On Abbreviated New Drug Applications With The US Food And Drug Adminis...
Novo Nordisk has received notifications from several manufacturers that they have filed Abbreviated New Drug Applications (ANDAs) for liraglutide, the active pharmaceutical molecule in Victoza®...
-
15Dec, 2023
The Performance Of The Double Heroes Of Weight Loss Drugs Has Exceeded Expect...
Novo Nordisk and Eli Lilly announced its Q3 financial results, and the GLP-1 revenues were unbeatable, and it continued to soar on the road becoming a phenomenal product. Novo Nordisk's total r...
-
15Dec, 2023
GlobalData: Eli Lilly’s Weight Loss Drug Zepbound Will Sell $4.1 Billion in T...
Weight loss drugs Weight loss drugs are drugs that have the effect of weight loss. At present, the weight loss drugs in clinical use include glucagon-like-peptide-1 (GLP-1), orlistat, lorcaserin hy...
Home /